The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer

Seminars in Oncology

Volumn 30, Issue 4 SUPPL. 10, 2003, Pages 37-44

  Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOCETAXEL; FOLIC ACID ANTAGONIST; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RASH; SKIN TOXICITY; VITAMIN SUPPLEMENTATION;

EID: 0041464768     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00284-7     Document Type: Conference Paper

References (50)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999
2. Devesa SS, Grauman DJ, Blot WJ, et al: Cancer surveillance series: Changing geographic patterns of lung cancer mortality in the United States, 1950 through 1994. J Natl Cancer Inst 91:1040-1050, 1999
3. Levi F, Lucchini F, Negri E, et al: Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994. Eur J Cancer 35:1477-1516, 1999
4. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics, 2000. CA Cancer J Clin 50:7-33, 2000
5. Van Zandwijk N, Pastorino U, De Vries N, et al: Randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: The Euroscan study. Proc Am Soc Clin Oncol 18:464a, 1999 (abstr 1788)
6. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:889-909, 1995
7. Huang P, Chubb S, Hertel LW, et al: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
8. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine). Cancer Res 50:4417-4422, 1990
9. Burris HA III, Moore MJ, Andersen J, et al: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
10. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15:744-749, 1997
11. Gatzemeier U, Sheperd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study. Eur J Cancer 32A:243-248, 1996
12. Von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, III study. J Clin Oncol 18:3068-3077, 2000
13. Delbaldo C, Faivre S, Monnerat C, et al: Nouveaux médicaments dans le cancer bronchique [New drugs in bronchial cancer]. Presse Med 31:802-809, 2002
14. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
15. Steward WP, Dunlop DJ, Dabouis G, et al: Phase III study of gemcitabine and cisplatin in non-small cell lung cancer: Preliminary results. Semin Oncol 23:43-47, 1996 (suppl 10)
16. Sandler A, Crino L, Steward WP, et al: Extended survival in stage III and IV non small cell lung cancer (NSCLC) patients treated with gemcitabine plus monthly cisplatin. Ann Oncol 7:91a, 1996 (suppl 5) (abstr)
17. Abratt RP, Sandler A, Crino L, et al: Combined cisplatin and gemcitabine for non-small cell lung cancer: Influence of scheduling on toxicity and drug delivery. Semin Oncol 25:35-43, 1998 (suppl 9)
18. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer. A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2000
19. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
20. Scagliotti GV, De Marinis F, Rinaldi M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non small cell lung cancer. J Clin Oncol 20:4285-4291, 2002
21. Sandler AB, Nemunaitis J, Denham C, et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130, 2000
22. Crino L, Scagliotti GV, Ricci S, et al: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530, 1999
23. Melo MJ, Barradas P, Costa A, et al: Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): Mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc Am Soc Clin Oncol 21:302a, 2002 (abstr 1205)
24. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12-18, 1999
25. Alberola V, Camps C, Provencia M, et al: Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): Results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02). Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1229)
26. Van Meerbeeck JP, Smit EF, Lianes P, et al: A EORTC randomized phase III trial of three chemotherapy regimens in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1228)
27. Bissett D, O'Byrne KJ, Von Pawel J, et al: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:296a, 2002 (abstr 1183)
28. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1162)
29. Rudd RM, Gower NH, James LE, et al: Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1164)
30. Gridelli C, Perone F, Cigolari S, et al: The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase III trial: Gemcitabine plus vinorelbine vs vinorelbine vs gemcitabine in elderly advanced NSCLC patients. Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1230)
31. Woynarowski JM, Faivre S, Herzig MC, et al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920-927, 2000
32. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 25:4-12, 1998 (suppl 5)
33. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865, 1996
34. Raymond E, Lawrence R, Izbicka E, et al: Activity of oxaliplatin against colony-forming units. Clin Cancer Res 4:1021-1029, 1998
35. Raymond E, Chaney SG, Taamma A, et al: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9:1053-1071, 1998
36. Faivre S, Le Chevalier T, Monnerat C, et al: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non small cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479-1489, 2002
37. Shewach DS, Hahn TM, Chang E, et al: Metabolism of 2′,2′-difluoro-2′-deoxycytidine radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218-3223, 1994
38. Gregor A: Gemcitabine plus radiotherapy for non small cell lung cancer. Semin Oncol 24:S8-39-S8-41, 1997 (suppl 8)
39. Vokes EE, Leopold KA, Herndon JE II, et al: A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) in stage IIIB non-small cell lung cancer (NSCLC): Feasibility data (CALGB study 9431). Proc Am Soc Clin Oncol 16:455a, 1997 (abstr 1636)
40. Van Zandwijk N, Smit EF, Kramer GW, et al: Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non small cell lung cancer: A phase II study of the European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 18:2658-2664, 2000
41. Rusthoven J, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1199, 1999
42. Clarke S, Millward M, Findlay M, et al: Activity of the multitargeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 9:86, 1998 (abstr 416P)
43. Rinaldi DA, Kuhn JG, Burris HA, et al: A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372-380, 1999
44. Smit EF, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003
45. Thodtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17: 3009-3016, 1999
46. Manegold C, Gatzemeier U, von Pawel J, et al: Frontline treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 11:435-440, 2000
47. Shepherd FA, Dancey J, Arnold A, et al: Phase 11 study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma. Cancer 92:595-600, 2001
48. Adjei AA, Erlichman C, Sloan JA, et al: A phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18:1748-1757, 2000
49. Ettinger DS, Monnerat C, Kelly K, et al: Phase II trial of pemetrexed plus gemcitabine in patients with advanced non small cell lung cancer: Importance of survival over response. Proc Am Soc Clin Oncol 21:311a, 2002 (abstr 1243)
50. Niyikiza C, Baker S, Johnson R, et al: MTA (LY231514): Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity. Ann Oncol 9:125, 1998 (abstr 609P)